RPL15

Large ribosomal subunit protein eL15 · P61313 · RPL15 on Sugi Atlas →

3,608 patent compounds predicted against RPL15, 1,876 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL15 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia	PHASE2	COMPLETED
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Role of Piwi-protein Interacting RNA, miRNA-194 and Amino Acids in Patients With Prostate Cancer	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
RibOSE - Glucose and Resistance Exercise Training	nan	COMPLETED
Proteomic Profiling to Reveal Novel Prognostic Markers for Neurological Outcome Following Resuscitation	nan	COMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPL15 binder may also engage these)

Protein	Name	Similarity
Q9CZM2	—	0.995	Q9CZM2 →
G1T0C1	—	0.991	G1T0C1 →
Q5NVE0	—	0.991	Q5NVE0 →
Q4R5B2	—	0.987	Q4R5B2 →
P61314	—	0.987	P61314 →
Q5EAD6	—	0.986	Q5EAD6 →
E2QXF3	—	0.986	E2QXF3 →
Q90YV2	—	0.976	Q90YV2 →
Q7T3N2	—	0.972	Q7T3N2 →
P79324	—	0.971	P79324 →
P51417	—	0.970	P51417 →
P61369	—	0.969	P61369 →
Q7T3N8	—	0.969	Q7T3N8 →
Q7T3M9	—	0.966	Q7T3M9 →
Q7T3N1	—	0.965	Q7T3N1 →
P61367	—	0.965	P61367 →
Q7T3P1	—	0.964	Q7T3P1 →
Q7T3N9	—	0.962	Q7T3N9 →
Q7T3N7	—	0.962	Q7T3N7 →
Q7T3P0	—	0.960	Q7T3P0 →
Q7T2N4	—	0.960	Q7T2N4 →
P61368	—	0.960	P61368 →
Q7T2N5	—	0.958	Q7T2N5 →
Q7T3N6	—	0.957	Q7T3N6 →
Q7T3N3	—	0.954	Q7T3N3 →
Q7T3N4	—	0.953	Q7T3N4 →
Q8X034	—	0.946	Q8X034 →
O13418	—	0.929	O13418 →
Q9GRJ3	—	0.923	Q9GRJ3 →
Q08200	—	0.922	Q08200 →